Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.

Date publication

octobre 2010

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline

Tous les auteurs :
Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, Ohira T, Tsuboi M, Matsubayashi J, Nagao T, Ikeda N, Hirsch FR

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/20697298

Résumé

Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) predict better outcome to EGFR tyrosine kinase inhibitors. The most common mutations are exon 19 deletions (most frequently E746-A750) and L858R point mutation in exon 21. Here, we evaluated the accuracy of novel EGFR mutation-specific antibodies in a Japanese cohort with NSCLC and compared with direct DNA sequencing and clinical outcome.

Mots clés

Adenocarcinoma, genetics, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, immunology, Carcinoma, Large Cell, genetics, Carcinoma, Non-Small-Cell Lung, genetics, Carcinoma, Squamous Cell, genetics, Cohort Studies, DNA, Neoplasm, genetics, ErbB Receptors, genetics, Female, Follow-Up Studies, Humans, Immunoenzyme Techniques, Lung Neoplasms, genetics, Male, Middle Aged, Mutation, genetics, Neoplasm Staging, Polymerase Chain Reaction, Prognosis, Retrospective Studies, Sensitivity and Specificity, Tissue Array Analysis

Référence

J Thorac Oncol. 2010 Oct;5(10):1551-8